Thermo Fisher Scientific launches two new Mass spectrometers to accelerate scientific discovery

SA—Thermo Fisher Scientific Inc., a global leader in scientific solutions, has announced the launch of two groundbreaking instruments: the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer and the Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer.

These new tools are designed to push the frontiers of scientific research, particularly in understanding complex diseases such as Alzheimer’s and cancer, and to advance the field of precision medicine.

The newly unveiled Orbitrap Astral Zoom and Orbitrap Excedion Pro mass spectrometers offer unmatched analytical performance and speed.

By enabling scientists to uncover intricate biological processes, these instruments are expected to pave the way for significant breakthroughs in disease research and drug development.

Thermo Fisher’s latest innovations further strengthen its comprehensive portfolio, providing a powerful and connected ecosystem that supports customers in proteomics, biopharmaceutical development, and scientific research.

Marc N. Casper, Thermo Fisher’s chairman, president, and CEO, emphasized the company’s ongoing commitment to innovation.

He described the new Orbitrap instruments as a major leap forward in mass spectrometry, allowing researchers worldwide to accelerate their discoveries and drive transformative scientific advancements.

 Casper also highlighted that Thermo Fisher offers one of the most extensive portfolios for omics and proteomics research—ranging from reagents and consumables to advanced imaging systems and cutting-edge mass spectrometry workflows.

These solutions enable scientists to measure and validate proteins with unprecedented precision and at a larger scale than ever before.

Building on the success of the award-winning Orbitrap Astral mass spectrometer, the new Orbitrap Astral Zoom MS is engineered to deliver even greater performance.

 It boasts 35% faster scan speeds, 40% higher throughput, and 50% expanded multiplexing capabilities, resulting in higher sensitivity and more flexible experiments.

With these improvements, researchers can extract richer data from their samples, accelerating discoveries that could shape the future of biopharmaceutical innovation.

Yu-Ju Chen, Ph.D., Distinguished Research Fellow at Academia Sinica, noted that the Orbitrap Astral Zoom mass spectrometer represents a paradigm shift in proteomics technology.

According to Dr. Chen, the instrument’s enhanced depth and coverage allow scientists to identify more potential biomarkers, which is crucial for early disease detection and precision oncology.

 These advances, he said, mark an important milestone in translating proteomics research into real-world clinical applications.

Meanwhile, the Thermo Scientific Orbitrap Excedion Pro MS builds on the renowned sensitivity, resolution, and accuracy of Orbitrap technology.

 It is the first platform to combine next-generation Orbitrap hybrid mass spectrometry with alternative fragmentation technologies, making it especially effective for analyzing complex biomolecules.

 This enables researchers to gain deeper insights into biotherapeutics such as monoclonal antibodies, which are vital for developing new treatments in cardiology, neurology, and oncology.

 With improved sensitivity, dynamic range, and reliability, the Excedion Pro MS delivers faster, higher-quality data on proteins, post-translational modifications, and small molecules, supporting robust biological discoveries.

Thermo Fisher will officially introduce the Orbitrap Astral Zoom MS and Orbitrap Excedion Pro MS at the American Society for Mass Spectrometry (ASMS) annual conference, held from June 1–5, 2025, in Baltimore, Maryland.

During the event, experts from Thermo Fisher and its partners will showcase the latest advances in instrumentation and software through presentations and live demonstrations.

Additionally, Thermo Fisher will highlight Olink’s innovative affinity-based proteomics technology at ASMS.

This technology offers exceptional specificity and sensitivity, and when combined with Orbitrap-based mass spectrometry, it empowers researchers to explore the causes, effects, and treatments of diseases more deeply than ever before.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.